Antithrombotics

Effects Antithrombotic Anticoagulant Fibrinolytic Active ingredients Salicylates: Acetylsalicylic acid 100 mg (Aspirin Cardio). P2Y12 antagonists: Clopidogrel (Plavix, generics). Prasugrel (Efient) Ticagrelor (Brilique) GP IIb/IIIa antagonists: Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) PAR-1 antagonists: Vorapaxar (Zontivity) Vitamin K antagonists (coumarins): Phenprocoumon (Marcoumar). Acenocoumarol (Sintrom) Not on sale in many countries: dicoumarol, warfarin. Heparins: Heparin sodium Heparin-Calcium … Antithrombotics

Low-Molecular-Weight Heparins

Products Low-molecular-weight heparins are commercially available as injectable solutions, in the form of prefilled syringes, ampoules, and lancing ampoules. The active ingredients now commonly used in many countries were first approved in the late 1980s. Biosimilars are available in some countries. The active ingredients are abbreviated in English with the acronym LMWH (low molecular weight … Low-Molecular-Weight Heparins

Mono-Embolex

Introduction Mono-Embolex® is a so-called anticoagulant, i.e. a drug that inhibits blood coagulation (anticoagulant) and is thus used primarily for the prophylaxis and therapy of venous thrombosis and pulmonary embolism. The active ingredient of the preparation Mono-Embolex® is certoparin sodium. The active ingredient Certoparin belongs to the class of low molecular weight (=fractionated) heparins. These … Mono-Embolex

Fields of application | Mono-Embolex

Fields of application Low molecular weight heparins such as the active ingredient certoparin in Mono-Embolex® are suitable for thrombosis prophylaxis and thrombosis therapy. Thrombosis is a disease that occurs in the blood vessels. A blood clot is formed via the coagulation cascade, which closes the blood vessel. Often thromboses are localized in the veins and … Fields of application | Mono-Embolex

Therapy monitoring | Mono-Embolex

Therapy monitoring In contrast to a standard heparin, the fluctuations of the drug level in the body are significantly lower with low-molecular-weight heparin. For this reason, therapy monitoring is usually not absolutely necessary. Exceptions are patients who have an increased risk of bleeding and/or patients who suffer from renal insufficiency. In such cases, the determination … Therapy monitoring | Mono-Embolex

Certoparin

Products Certoparin was commercially available as a solution for injection (Sandoparin, off label). It was approved in many countries from 1989 to 2018. Structure and properties Certoparin is present in drugs as certoparin sodium. Effects Certoparin (ATC B01AB01) has antithrombotic properties. The effects are primarily due to inhibition of coagulation factor Xa by complexation with … Certoparin